Typical merger/ TO/ licence deal scenario.
The great news and milestone achievements keep coming and price is held low.
This is like a coiled spring, the longer we are kept this low, the more massive the eventual
breakout.
The outome is the same, a SP of 35 to 50 cents at the onset of clinical trials mid next year with a ' significantly expanded pipeline ' in CNS and kidney, which was now officially taken into the timeline graphs for the first time.
To expand to CNS, kidney on a meaningful, multiple programs per pipeline spannning dimension, a lot of additional funding needs to come to the company.
We are in the preludes of that event, hence being held low, spurs of accumulation followed by price control on low volume.
This goes on until it does not and then adding to ones portfolio will come at a massive price increase.
all IMO
PYC Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)